Divided US FDA AdComm Backs Molnupiravir Authorization But Wants More Studies

 
• By Brenda Sandburg

In 13-10 vote, panel finds reduction in COVID-19 hospitalizations and deaths outweighs risks. Four members say FDA should reconsider authorization if a more effective and safer therapy comes along. They concur molnupiravir should not be recommended for use in pregnancy but available to those who want it.

Molnupiravir
US FDA advisory committee favors FDA authorization of Merck's molnupiravir • Source: Alamy

More from US FDA Performance Tracker

More from Regulatory Trackers